Skip to main content
رجوع
VBIZF logo

Viva Biotech Holdings

جودة البيانات: 100%
ذروة شراء
VBIZF
OTC Healthcare Biotechnology
KWD 0.34
KWD 0.00 (0.00%)
القيمة السوقية: 724.45M
نطاق اليوم
KWD 0.30 KWD 0.34
نطاق 52 أسبوعًا
KWD 0.18 KWD 0.43
حجم التداول
100
متوسط 50 يوم / 200 يوم
KWD 0.31 / KWD 0.27
الإغلاق السابق
KWD 0.34

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 4.3 0.3
P/B 0.2 2.9
ROE % 4.5 3.7
Net Margin % 8.4 3.8
Rev Growth 5Y % 29.9 10.0
D/E 0.3 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2029 KWD 0.000
KWD 0.000 – KWD 0.000
840 M 0
FY2028 KWD 0.000
KWD 0.000 – KWD 0.000
1 B 0
FY2027 KWD 0.162
KWD 0.162 – KWD 0.162
2.7 B 1

النقاط الرئيسية

Revenue grew 29.94% annually over 5 years — strong growth
ROE of 4.47% is below average
Debt/Equity of 0.34 — conservative balance sheet
Generating 182.32M in free cash flow
P/E of 4.33 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 37.78%

النمو

Revenue Growth (5Y)
29.94%
Revenue (1Y)-7.84%
Earnings (1Y)N/A
FCF Growth (3Y)15.48%

الجودة

Return on Equity
4.47%
ROIC3.98%
Net Margin8.42%
Op. Margin13.57%

الأمان

Debt / Equity
0.34
Current Ratio1.67
Interest Coverage5.00

التقييم

P/E Ratio
4.33
P/B Ratio0.19
EV/EBITDA3.96
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -7.84% Revenue Growth (3Y) -8.63%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 29.94% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.99B Net Income (TTM) 167.29M
ROE 4.47% ROA 2.37%
Gross Margin 34.60% Operating Margin 13.57%
Net Margin 8.42% Free Cash Flow (TTM) 182.32M
ROIC 3.98% FCF Growth (3Y) 15.48%
Safety
Debt / Equity 0.34 Current Ratio 1.67
Interest Coverage 5.00 Dividend Yield 0.00%
Valuation
P/E Ratio 4.33 P/B Ratio 0.19
P/S Ratio 0.36 PEG Ratio -0.03
EV/EBITDA 3.96 Dividend Yield 0.00%
Market Cap 724.45M Enterprise Value 1.07B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1.99B 2.16B 2.38B 2.10B 696.96M
Net Income 167.29M -116.11M -528.48M 287.55M -386.88M
EPS (Diluted) 0.06 -0.06 -0.28 0.15 -0.25
Gross Profit 687.40M 738.43M 815.68M 650.98M 304.87M
Operating Income 269.59M 192.68M 269.35M 236.90M 115.57M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 7.05B 7.45B 7.92B 8.04B 8.15B
Total Liabilities 3.23B 3.76B 4.32B 4.13B 4.40B
Shareholders' Equity 3.80B 3.69B 3.60B 3.91B 3.76B
Total Debt 1.28B 1.90B 2.82B 2.65B 2.97B
Cash & Equivalents 941.58M 1.04B 678.57M 800.95M 2.31B
Current Assets 1.88B 2.03B 1.94B 1.98B 3.35B
Current Liabilities 1.13B 1.53B 2.67B 926.60M 735.67M

درجات الاستراتيجيات

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches

النشاط الأخير

دخل Deep Value Investing (Seth Klarman)
Mar 24, 2026
دخل Defensive Investing (Benjamin Graham)
Mar 24, 2026